Click here to get full coverage on (ALKS) and the Role of Price-Sensitive Allocations - Stock Traders Daily

(ALKS) and the Role of Price-Sensitive Allocations  Stock Traders Daily

(ALKS) and the Role of Price-Sensitive Allocations - Stock Traders Daily

Click here to get full coverage on A Look At Alkermes (ALKS) Valuation As CEO Transition And Softer Earnings Reset Expectations - simplywall.st

A Look At Alkermes (ALKS) Valuation As CEO Transition And Softer Earnings Reset Expectations  simplywall.st

A Look At Alkermes (ALKS) Valuation As CEO Transition And Softer Earnings Reset Expectations - simplywall.st

Click here to get full coverage on Alkermes plc Reports Third Quarter 2025 Financial Results - PR Newswire

Alkermes plc Reports Third Quarter 2025 Financial Results  PR Newswire

Alkermes plc Reports Third Quarter 2025 Financial Results - PR Newswire

Click here to get full coverage on Alkermes Advances ALKS 2680 Into Phase 3 for Narcolepsy Type 1: What Investors Should Watch - TipRanks

Alkermes Advances ALKS 2680 Into Phase 3 for Narcolepsy Type 1: What Investors Should Watch  TipRanks

Alkermes Advances ALKS 2680 Into Phase 3 for Narcolepsy Type 1: What Investors Should Watch - TipRanks

Click here to get full coverage on Alkermes (NASDAQ:ALKS) EVP Sells $59,575.86 in Stock - MarketBeat

Alkermes (NASDAQ:ALKS) EVP Sells $59,575.86 in Stock  MarketBeat

Alkermes (NASDAQ:ALKS) EVP Sells $59,575.86 in Stock - MarketBeat

Click here to get full coverage on ALKS: Major advances in sleep medicine and orexin pipeline drive growth and future opportunities - TradingView

ALKS: Major advances in sleep medicine and orexin pipeline drive growth and future opportunities  TradingView

ALKS: Major advances in sleep medicine and orexin pipeline drive growth and future opportunities - TradingView

Click here to get full coverage on Alkermes (ALKS) Reports Q4 Earnings: What Key Metrics Have to Say - Yahoo Finance

Alkermes (ALKS) Reports Q4 Earnings: What Key Metrics Have to Say  Yahoo Finance

Alkermes (ALKS) Reports Q4 Earnings: What Key Metrics Have to Say - Yahoo Finance

Click here to get full coverage on Orexin Receptor Agent ALKS 2680 Meets End Points in Phase 2 VIBRANCE-1 Study - NeurologyLive

Orexin Receptor Agent ALKS 2680 Meets End Points in Phase 2 VIBRANCE-1 Study  NeurologyLive

Orexin Receptor Agent ALKS 2680 Meets End Points in Phase 2 VIBRANCE-1 Study - NeurologyLive

Click here to get full coverage on ALKERMES ($ALKS) Releases Q4 2025 Earnings - Quiver Quantitative

ALKERMES ($ALKS) Releases Q4 2025 Earnings  Quiver Quantitative

ALKERMES ($ALKS) Releases Q4 2025 Earnings - Quiver Quantitative

Click here to get full coverage on Analysts’ Opinions Are Mixed on These Healthcare Stocks: Arcellx Inc (ACLX), Alkermes (ALKS) and Progyny (PGNY) - The Globe and Mail

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Arcellx Inc (ACLX), Alkermes (ALKS) and Progyny (PGNY)  The Globe and Mail

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Arcellx Inc (ACLX), Alkermes (ALKS) and Progyny (PGNY) - The Globe and Mail

Click here to get full coverage on Wall Street's Insights Into Key Metrics Ahead of Alkermes (ALKS) Q4 Earnings - Nasdaq

Wall Street's Insights Into Key Metrics Ahead of Alkermes (ALKS) Q4 Earnings  Nasdaq

Wall Street's Insights Into Key Metrics Ahead of Alkermes (ALKS) Q4 Earnings - Nasdaq

Click here to get full coverage on Christian Todd Nichols Sells 6,000 Shares of Alkermes (NASDAQ:ALKS) Stock - MarketBeat

Christian Todd Nichols Sells 6,000 Shares of Alkermes (NASDAQ:ALKS) Stock  MarketBeat

Christian Todd Nichols Sells 6,000 Shares of Alkermes (NASDAQ:ALKS) Stock - MarketBeat

Click here to get full coverage on Alkermes to Present Detailed Positive Results From Vibrance-1 Phase 2 Study Evaluating Alixorexton in Patients With Narcolepsy Type 1 at World Sleep 2025 - PR Newswire

Alkermes to Present Detailed Positive Results From Vibrance-1 Phase 2 Study Evaluating Alixorexton in Patients With Narcolepsy Type 1 at World Sleep 2025  PR Newswire

Alkermes to Present Detailed Positive Results From Vibrance-1 Phase 2 Study Evaluating Alixorexton in Patients With Narcolepsy Type 1 at World Sleep 2025 - PR Newswire

Click here to get full coverage on Alkermes (ALKS) Q4 Earnings and Revenues Top Estimates - Yahoo Finance

Alkermes (ALKS) Q4 Earnings and Revenues Top Estimates  Yahoo Finance

Alkermes (ALKS) Q4 Earnings and Revenues Top Estimates - Yahoo Finance

Click here to get full coverage on Alkermes plc Reports Second Quarter 2025 Financial Results - PR Newswire

Alkermes plc Reports Second Quarter 2025 Financial Results  PR Newswire

Alkermes plc Reports Second Quarter 2025 Financial Results - PR Newswire

Click here to get full coverage on Is Alkermes (ALKS) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance

Is Alkermes (ALKS) Stock Outpacing Its Medical Peers This Year?  Yahoo Finance

Is Alkermes (ALKS) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance

Click here to get full coverage on Is Alkermes (ALKS) Pricing In Its Neuroscience And Orexin Pipeline Potential? - simplywall.st

Is Alkermes (ALKS) Pricing In Its Neuroscience And Orexin Pipeline Potential?  simplywall.st

Is Alkermes (ALKS) Pricing In Its Neuroscience And Orexin Pipeline Potential? - simplywall.st

Click here to get full coverage on A Look At Alkermes (ALKS) Valuation After Recent Mixed Share Price Performance - Yahoo Finance

A Look At Alkermes (ALKS) Valuation After Recent Mixed Share Price Performance  Yahoo Finance

A Look At Alkermes (ALKS) Valuation After Recent Mixed Share Price Performance - Yahoo Finance

Click here to get full coverage on Will Alkermes (ALKS) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance

Will Alkermes (ALKS) Beat Estimates Again in Its Next Earnings Report?  Yahoo Finance

Will Alkermes (ALKS) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance

Click here to get full coverage on Alkermes Appoints Joshua Reed as Chief Financial Officer - PR Newswire

Alkermes Appoints Joshua Reed as Chief Financial Officer  PR Newswire

Alkermes Appoints Joshua Reed as Chief Financial Officer - PR Newswire

Click here to get full coverage on Alkermes (ALKS) COO logs RSU share gain and tax-related share disposal - Stock Titan

Alkermes (ALKS) COO logs RSU share gain and tax-related share disposal  Stock Titan

Alkermes (ALKS) COO logs RSU share gain and tax-related share disposal - Stock Titan

Click here to get full coverage on Does Alkermes’ Weaker 2025 Results and CEO Changeover Shift the Bull Case for ALKS? - Yahoo Finance

Does Alkermes’ Weaker 2025 Results and CEO Changeover Shift the Bull Case for ALKS?  Yahoo Finance

Does Alkermes’ Weaker 2025 Results and CEO Changeover Shift the Bull Case for ALKS? - Yahoo Finance

Click here to get full coverage on Alkermes’ 35-year CEO era ends as Blair Jackson takes the helm - Stock Titan

Alkermes’ 35-year CEO era ends as Blair Jackson takes the helm  Stock Titan

Alkermes’ 35-year CEO era ends as Blair Jackson takes the helm - Stock Titan

Click here to get full coverage on ALKS - Alkermes plc Reports Results for Fiscal 2012 and Provides Expectations for Fiscal 2013 - mx.advfn.com

ALKS - Alkermes plc Reports Results for Fiscal 2012 and Provides Expectations for Fiscal 2013  mx.advfn.com

ALKS - Alkermes plc Reports Results for Fiscal 2012 and Provides Expectations for Fiscal 2013 - mx.advfn.com

Click here to get full coverage on Alkermes Announces Positive Topline Results From Vibrance-1 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 1 - PR Newswire

Alkermes Announces Positive Topline Results From Vibrance-1 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 1  PR Newswire

Alkermes Announces Positive Topline Results From Vibrance-1 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 1 - PR Newswire

Click here to get full coverage on American Century Companies Inc. Purchases 740,248 Shares of Alkermes plc $ALKS - MarketBeat

American Century Companies Inc. Purchases 740,248 Shares of Alkermes plc $ALKS  MarketBeat

American Century Companies Inc. Purchases 740,248 Shares of Alkermes plc $ALKS - MarketBeat

Click here to get full coverage on Is Alkermes (ALKS) Stock Undervalued Right Now? - Yahoo Finance

Is Alkermes (ALKS) Stock Undervalued Right Now?  Yahoo Finance

Is Alkermes (ALKS) Stock Undervalued Right Now? - Yahoo Finance

Click here to get full coverage on ALKS Raises Its Offer to Buy Avadel In Response to Lundbeck's Proposal - Yahoo Finance

ALKS Raises Its Offer to Buy Avadel In Response to Lundbeck's Proposal  Yahoo Finance

ALKS Raises Its Offer to Buy Avadel In Response to Lundbeck's Proposal - Yahoo Finance

Click here to get full coverage on Will Debt-Funded Avadel Deal and 2026 CEO Shift Change Alkermes' (ALKS) Narrative? - simplywall.st

Will Debt-Funded Avadel Deal and 2026 CEO Shift Change Alkermes' (ALKS) Narrative?  simplywall.st

Will Debt-Funded Avadel Deal and 2026 CEO Shift Change Alkermes' (ALKS) Narrative? - simplywall.st

Click here to get full coverage on ALKS: 2026 outlook projects strong revenue growth, LUMRYZ integration, and pipeline advancement - TradingView

ALKS: 2026 outlook projects strong revenue growth, LUMRYZ integration, and pipeline advancement  TradingView

ALKS: 2026 outlook projects strong revenue growth, LUMRYZ integration, and pipeline advancement - TradingView

Click here to get full coverage on Alkermes (NASDAQ: ALKS) adds LUMRYZ with Avadel deal, expands CNS focus - Stock Titan

Alkermes (NASDAQ: ALKS) adds LUMRYZ with Avadel deal, expands CNS focus  Stock Titan

Alkermes (NASDAQ: ALKS) adds LUMRYZ with Avadel deal, expands CNS focus - Stock Titan

Click here to get full coverage on Responsive Playbooks and the ALKS Inflection - Stock Traders Daily

Responsive Playbooks and the ALKS Inflection  Stock Traders Daily

Responsive Playbooks and the ALKS Inflection - Stock Traders Daily

Click here to get full coverage on Is Alkermes (ALKS) Outperforming Other Medical Stocks This Year? - Yahoo Finance

Is Alkermes (ALKS) Outperforming Other Medical Stocks This Year?  Yahoo Finance

Is Alkermes (ALKS) Outperforming Other Medical Stocks This Year? - Yahoo Finance

Click here to get full coverage on Alkermes (ALKS) Reports Q3 Earnings: What Key Metrics Have to Say - Yahoo Finance

Alkermes (ALKS) Reports Q3 Earnings: What Key Metrics Have to Say  Yahoo Finance

Alkermes (ALKS) Reports Q3 Earnings: What Key Metrics Have to Say - Yahoo Finance

Click here to get full coverage on Analysts Just Made An Incredible Upgrade To Their Alkermes plc (NASDAQ:ALKS) Forecasts - Yahoo Finance

Analysts Just Made An Incredible Upgrade To Their Alkermes plc (NASDAQ:ALKS) Forecasts  Yahoo Finance

Analysts Just Made An Incredible Upgrade To Their Alkermes plc (NASDAQ:ALKS) Forecasts - Yahoo Finance

Click here to get full coverage on Brigita Anna Alks Obituary August 8, 2025 - Lombardo Funeral Home

Brigita Anna Alks Obituary August 8, 2025  Lombardo Funeral Home

Brigita Anna Alks Obituary August 8, 2025 - Lombardo Funeral Home

Click here to get full coverage on Alkermes (NASDAQ:ALKS) Issues Earnings Results, Misses Expectations By $0.14 EPS - MarketBeat

Alkermes (NASDAQ:ALKS) Issues Earnings Results, Misses Expectations By $0.14 EPS  MarketBeat

Alkermes (NASDAQ:ALKS) Issues Earnings Results, Misses Expectations By $0.14 EPS - MarketBeat

Click here to get full coverage on Alkermes plc $ALKS Stake Lessened by Vanguard Group Inc. - MarketBeat

Alkermes plc $ALKS Stake Lessened by Vanguard Group Inc.  MarketBeat

Alkermes plc $ALKS Stake Lessened by Vanguard Group Inc. - MarketBeat

Click here to get full coverage on Assessing Alkermes (ALKS) Valuation After Recent Share Price Swings - simplywall.st

Assessing Alkermes (ALKS) Valuation After Recent Share Price Swings  simplywall.st

Assessing Alkermes (ALKS) Valuation After Recent Share Price Swings - simplywall.st

Click here to get full coverage on Vibrance-3: Study Design and Methods for a Phase 2, Randomized, Placebo Controlled, Parallel-Group Study Evaluating the Safety and Efficacy of ALKS 2680 in Patients With Idiopathic Hypersomnia - NeurologyLive

Vibrance-3: Study Design and Methods for a Phase 2, Randomized, Placebo Controlled, Parallel-Group Study Evaluating the Safety and Efficacy of ALKS 2680 in Patients With Idiopathic Hypersomnia  NeurologyLive

Vibrance-3: Study Design and Methods for a Phase 2, Randomized, Placebo Controlled, Parallel-Group Study Evaluating the Safety and Efficacy of ALKS 2680 in Patients With Idiopathic Hypersomnia - NeurologyLive

Click here to get full coverage on Why Analysts are Rating Alkermes (ALKS) a Buy - Yahoo Finance

Why Analysts are Rating Alkermes (ALKS) a Buy  Yahoo Finance

Why Analysts are Rating Alkermes (ALKS) a Buy - Yahoo Finance

Click here to get full coverage on Alkermes PLC (ALKS) Q4 2025 Earnings Call Highlights: Strong Rev - GuruFocus

Alkermes PLC (ALKS) Q4 2025 Earnings Call Highlights: Strong Rev  GuruFocus

Alkermes PLC (ALKS) Q4 2025 Earnings Call Highlights: Strong Rev - GuruFocus

Click here to get full coverage on Is Alkermes (ALKS) Pricing Reflect Its DCF Value Gap And Recent Mixed Returns - Yahoo Finance

Is Alkermes (ALKS) Pricing Reflect Its DCF Value Gap And Recent Mixed Returns  Yahoo Finance

Is Alkermes (ALKS) Pricing Reflect Its DCF Value Gap And Recent Mixed Returns - Yahoo Finance

Click here to get full coverage on Alkermes to review 2025 results, 2026 financial expectations on Feb. 25 - Stock Titan

Alkermes to review 2025 results, 2026 financial expectations on Feb. 25  Stock Titan

Alkermes to review 2025 results, 2026 financial expectations on Feb. 25 - Stock Titan

Click here to get full coverage on Alkermes Announces Initiation of Vibrance-3 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Idiopathic Hypersomnia - PR Newswire

Alkermes Announces Initiation of Vibrance-3 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Idiopathic Hypersomnia  PR Newswire

Alkermes Announces Initiation of Vibrance-3 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Idiopathic Hypersomnia - PR Newswire

Click here to get full coverage on JPMorgan Chase & Co. Sells 908,124 Shares of Alkermes plc $ALKS - MarketBeat

JPMorgan Chase & Co. Sells 908,124 Shares of Alkermes plc $ALKS  MarketBeat

JPMorgan Chase & Co. Sells 908,124 Shares of Alkermes plc $ALKS - MarketBeat

Click here to get full coverage on Aberdeen Group plc Sells 32,495 Shares of Alkermes plc $ALKS - MarketBeat

Aberdeen Group plc Sells 32,495 Shares of Alkermes plc $ALKS  MarketBeat

Aberdeen Group plc Sells 32,495 Shares of Alkermes plc $ALKS - MarketBeat

Click here to get full coverage on Alkermes (ALKS) Announces CEO Transition as Shares Dip - GuruFocus

Alkermes (ALKS) Announces CEO Transition as Shares Dip  GuruFocus

Alkermes (ALKS) Announces CEO Transition as Shares Dip - GuruFocus

Click here to get full coverage on Understanding ALKS 2680’s Wake-Promoting Effects Through qEEG: Julia Chapman, PhD - NeurologyLive

Understanding ALKS 2680’s Wake-Promoting Effects Through qEEG: Julia Chapman, PhD  NeurologyLive

Understanding ALKS 2680’s Wake-Promoting Effects Through qEEG: Julia Chapman, PhD - NeurologyLive

Click here to get full coverage on Alkermes PLC (ALKS) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Expansion - Yahoo Finance

Alkermes PLC (ALKS) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Expansion  Yahoo Finance

Alkermes PLC (ALKS) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Expansion - Yahoo Finance

Click here to get full coverage on Alkermes (NASDAQ: ALKS) notes Avadel must give 5 Business Days’ notice, negotiate - Stock Titan

Alkermes (NASDAQ: ALKS) notes Avadel must give 5 Business Days’ notice, negotiate  Stock Titan

Alkermes (NASDAQ: ALKS) notes Avadel must give 5 Business Days’ notice, negotiate - Stock Titan

Click here to get full coverage on $ALKS stock is down 18% today. Here's what we see in our data. - Quiver Quantitative

$ALKS stock is down 18% today. Here's what we see in our data.  Quiver Quantitative

$ALKS stock is down 18% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on Wells Fargo Boosts Price Target for Alkermes (ALKS), Maintains O - GuruFocus

Wells Fargo Boosts Price Target for Alkermes (ALKS), Maintains O  GuruFocus

Wells Fargo Boosts Price Target for Alkermes (ALKS), Maintains O - GuruFocus

Click here to get full coverage on Does Alkermes (ALKS) Have the Potential to Rally 36.3% as Wall Street Analysts Expect? - Zacks Investment Research

Does Alkermes (ALKS) Have the Potential to Rally 36.3% as Wall Street Analysts Expect?  Zacks Investment Research

Does Alkermes (ALKS) Have the Potential to Rally 36.3% as Wall Street Analysts Expect? - Zacks Investment Research

Click here to get full coverage on Alkermes (ALKS) Q4 2025 Earnings Call Transcript - The Globe and Mail

Alkermes (ALKS) Q4 2025 Earnings Call Transcript  The Globe and Mail

Alkermes (ALKS) Q4 2025 Earnings Call Transcript - The Globe and Mail

Click here to get full coverage on Alkermes (ALKS) Projects Strong Financial Growth and Strategic A - GuruFocus

Alkermes (ALKS) Projects Strong Financial Growth and Strategic A  GuruFocus

Alkermes (ALKS) Projects Strong Financial Growth and Strategic A - GuruFocus

Click here to get full coverage on ALKS to Enter Sleep Disorder Market With $2.1B Avadel Acquisition - Yahoo Finance

ALKS to Enter Sleep Disorder Market With $2.1B Avadel Acquisition  Yahoo Finance

ALKS to Enter Sleep Disorder Market With $2.1B Avadel Acquisition - Yahoo Finance

Click here to get full coverage on Alkermes (ALKS) Reports Strong Q4 Revenue, Sets Ambitious 2026 G - GuruFocus

Alkermes (ALKS) Reports Strong Q4 Revenue, Sets Ambitious 2026 G  GuruFocus

Alkermes (ALKS) Reports Strong Q4 Revenue, Sets Ambitious 2026 G - GuruFocus

Click here to get full coverage on Alkermes (NASDAQ:ALKS) Shares Down 6.7% on Disappointing Earnings - MarketBeat

Alkermes (NASDAQ:ALKS) Shares Down 6.7% on Disappointing Earnings  MarketBeat

Alkermes (NASDAQ:ALKS) Shares Down 6.7% on Disappointing Earnings - MarketBeat

Click here to get full coverage on ALKS: B of A Securities Raises Price Target While Maintaining Ne - GuruFocus

ALKS: B of A Securities Raises Price Target While Maintaining Ne  GuruFocus

ALKS: B of A Securities Raises Price Target While Maintaining Ne - GuruFocus

Click here to get full coverage on 81,800 Shares in Alkermes plc $ALKS Bought by Eagle Health Investments LP - MarketBeat

81,800 Shares in Alkermes plc $ALKS Bought by Eagle Health Investments LP  MarketBeat

81,800 Shares in Alkermes plc $ALKS Bought by Eagle Health Investments LP - MarketBeat

Click here to get full coverage on Assessing Alkermes (ALKS) Valuation After Its Recent Share Price Momentum - Yahoo Finance

Assessing Alkermes (ALKS) Valuation After Its Recent Share Price Momentum  Yahoo Finance

Assessing Alkermes (ALKS) Valuation After Its Recent Share Price Momentum - Yahoo Finance

Click here to get full coverage on Alkermes Announces Launch of 8th Annual Alkermes Pathways Research Awards® Program - PR Newswire

Alkermes Announces Launch of 8th Annual Alkermes Pathways Research Awards® Program  PR Newswire

Alkermes Announces Launch of 8th Annual Alkermes Pathways Research Awards® Program - PR Newswire

Click here to get full coverage on Alkermes (ALKS) Is Up 6.6% After FDA Breakthrough Tag for Narcolepsy Drug Alixorexton - Yahoo Finance

Alkermes (ALKS) Is Up 6.6% After FDA Breakthrough Tag for Narcolepsy Drug Alixorexton  Yahoo Finance

Alkermes (ALKS) Is Up 6.6% After FDA Breakthrough Tag for Narcolepsy Drug Alixorexton - Yahoo Finance

Click here to get full coverage on Alkermes (NASDAQ:ALKS) Stock Rating Upgraded by Wolfe Research - MarketBeat

Alkermes (NASDAQ:ALKS) Stock Rating Upgraded by Wolfe Research  MarketBeat

Alkermes (NASDAQ:ALKS) Stock Rating Upgraded by Wolfe Research - MarketBeat

Click here to get full coverage on Alkermes (ALKS) Q4 2025 Earnings Call Transcript - AOL.com

Alkermes (ALKS) Q4 2025 Earnings Call Transcript  AOL.com

Alkermes (ALKS) Q4 2025 Earnings Call Transcript - AOL.com

Click here to get full coverage on Alkermes plc Announces Agreement to Acquire Avadel Pharmaceuticals plc - PR Newswire

Alkermes plc Announces Agreement to Acquire Avadel Pharmaceuticals plc  PR Newswire

ALKS

Price Chart

Key Statistics

Technicals

About ALKS

Latest News

(ALKS) and the Role of Price-Sensitive Allocations - Stock Traders Daily

A Look At Alkermes (ALKS) Valuation As CEO Transition And Softer Earnings Reset Expectations - simplywall.st

Alkermes plc Reports Third Quarter 2025 Financial Results - PR Newswire

Advanced Charts

Top Gainers

Top Losers